López Ortega S, González Grande R, Santaella Leiva I, De la Cruz Lombardo J, Jiménez Pérez M
UGC Aparato Digestivo, Liver Unit, Regional University Hospital, Malaga, Spain.
UGC Aparato Digestivo, Liver Unit, Regional University Hospital, Malaga, Spain.
Transplant Proc. 2020 Mar;52(2):540-542. doi: 10.1016/j.transproceed.2019.12.016. Epub 2020 Feb 10.
Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is increasing, with a consequent impact on survival. Here we report our experience with sorafenib to treat HCC recurrence after LT. PATIENTS AND METHODS: We undertook a retrospective cohort study of LT patients with recurrent HCC. RESULTS: The study included 12 patients with recurrent HCC after LT between January 2008 and March 2019; 9 were men and 3 women, with a median age of 58 years. Adverse effects were manageable in most patients with symptomatic treatment or with sorafenib dose adjustment. Stable disease was the best response and was achieved. Eight patients (66.7%) died during the study period, 5 (62.5%) due to tumor progression and 3 (37.5%) because of sepsis. The median survival time was 7.5 months.
肝移植（LT）后肝细胞癌（HCC）的复发率正在上升，进而影响患者生存率。在此，我们报告使用索拉非尼治疗LT后HCC复发的经验。患者与方法：我们对LT后复发HCC的患者进行了一项回顾性队列研究。结果：该研究纳入了2008年1月至2019年3月期间LT后复发HCC的12例患者；其中9例为男性，3例为女性，中位年龄为58岁。大多数患者通过对症治疗或调整索拉非尼剂量，不良反应可控。疾病稳定是最佳反应且得以实现。8例患者（66.7%）在研究期间死亡，5例（62.5%）死于肿瘤进展，3例（37.5%）死于败血症。中位生存时间为7.5个月。
